TEST:

HTG Transcriptome Panel

It is feasible to determine consensus molecular subtypes of MIBC from FFPE samples. Classification is reliable also when employing reduced gene sets. In addition, consensus molecular subtypes exhibit a predictive value and might help with therapy decisions as the Ba/Sq subtype shows poorer OS, but seems to benefit more from platinum-based adjuvant chemotherapy.

ChILI has a different gene expression profile and immune cell distribution than AIH, supporting the notion that they are two distinct disease entities. However, both diseases share a similar T-cell repertoire architecture in liver biopsies. Interestingly, we detected overlapping T cell clones between ChILI and matched tumor samples, suggesting a role for shared epitopes between liver and tumor samples.

Notably, a 167-gene predictive signature was developed and validated in the phase II ipilimumab plus nivolumab salivary gland cancer trial. Correlative analysis of the phase II axitinib plus avelumab trial revealed potential biomarkers predictive of combination clinical benefit in ACC, including a gene-expression signature. These findings may guide patient stratification for combinatorial therapy.

ChILI has a different gene expression profile and immune cell distribution than AIH, supporting the notion that they are two distinct disease entities. However, both diseases share a similar T-cell repertoire architecture in liver biopsies. Interestingly, we detected overlapping T cell clones between ChILI and matched tumor samples, suggesting a role for shared epitopes between liver and tumor samples.

Background: KRAS G12C inhibitors (G12Ci) are revolutionizing the therapeutic landscape of advanced NSCLC, but mechanisms of limited clinical efficacy observed in some patients (pts) merit continued exploration. Co-mutations in KEAP1 and STK11 and NRF2 signaling define a subgroup of KG12C NSCLC pts with markedly distinct outcomes upon treatment with ada. The mTORi and ada combination shows high efficacy for targeting KG12C NSCLC harboring KEAP1 and STK11 co-mutations. The clinical safety and efficacy of mTORi nab-sirolimus and ada will be determined in the ongoing KRYSTAL-19 trial (NCT05840510).

LMO2 ISH by RNAscope method is reliable and can be applied in routine FFPE samples. Our series had good correlation with LMO2 gene expression and LMO2 IHC. Moreover, the prognostic impact on survival captured by LMO2 RNA ISH was similar to published for gene expression and IHC methods.

Determination of consensus molecular subtypes of MIBC from FFPE samples is feasible using various RNA sequencing methods. Inconsistent classification mainly involves the stroma-rich molecular subtype, which may be the consequence of sample heterogeneity with (stroma)-cell sampling bias and highlights the limitations of bulk RNA-based subclassification. Classification is still reliable when analysis is reduced to selected genes.

Clinical outcomes to axitinib plus avelumab were distinct between ACC-I and ACC-II subtypes, with ACC-II pts demonstrating an improved DCR and significantly longer PFS. Gene expression analysis revealed high expression of immune function-related genes in patients who benefited from axitinib plus avelumab in both ACC subtypes, indicating possible biomarkers predictive of benefit from the combination in ACC. Clinical trial information: NCT03990571.

"HTG Molecular Diagnostics, Inc...today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida."

IL23 is an especially appealing target given it is tumourogenic, has a favourable side effect profile and is effective in conventional inflammatory bowel disease (IBD). Further studies are needed to elucidate the role of anti-IL23 therapies in patients with CPI-colitis.

In conclusion, basal-like MIBC and the squamous histological subtype are associated with high nuclear KMT9α expression. The association with poor survival makes it a potential target for the treatment of bladder cancer.

"HTG Molecular Diagnostics, Inc...today announced there will be at least eight scientific abstracts featuring HTG’s proprietary HTG EdgeSeq™ technology presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS 2022) and at the 64th Annual American Society of Hematology (ASH) Annual Meeting."